Etid klinik pou Kansè ovè nan Virginia
57 etid pou Kansè ovè ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Ballad Health Cancer Care - Bristol, Bristol
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- ak 5 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Next Virginia /ID# 279684, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Oct 1, 2026 · NCT07024784A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Next Virginia /ID# 278607, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07278336A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- NEXT Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06799065A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0295 - Virginia Oncology Associates, Chesapeake
- Site 0322 - Inova Schar Cancer Institute, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- UVA Health University Hospital /ID# 275309, Charlottesville
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227, Norfolk
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Virginia Commonwealth University/ Massey Cancer Center, Richmond
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05051722Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Virginia Commonwealth University, Richmond
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Virginia Cancer Specialists (VCS) ( Site 8012), Fairfax
- Virginia Oncology Associates (VOA) ( Site 8013), Norfolk
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Virginia Cancer Specialists, Fairfax
- Carilion Clinic, Roanoke
Ap rekriteFaz 2
Laj 18 a 99 · Fanm · Mizajou Sep 15, 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Virginia Health System, Charlottesville
- Inova Schar Cancer Institute, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Inova Schar Cancer Institute, Fairfax
- Next Oncology Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- NEXT Oncology, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT07755436A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Virginia Cancer Specialists (VCS) ( Site 8011), Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- ak 5 plis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- University of Virginia, Charlottesville
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 21, 2026 · NCT05797168A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149A Study of PHST001 in Advanced Solid Tumors
- NEXT Oncology - Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06840886A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- ak 5 plis
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07444814A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07524322Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 522, Fairfax
- 300, Norfolk
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Jul 16, 2026 · NCT06906341Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Virginia, Richmond
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Jul 14, 2026 · NCT04606914Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.